<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290028</url>
  </required_header>
  <id_info>
    <org_study_id>CR016</org_study_id>
    <nct_id>NCT02290028</nct_id>
  </id_info>
  <brief_title>Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads</brief_title>
  <acronym>QP ExCELs</acronym>
  <official_title>Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotronik, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotronik SE &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The QP ExCELs study is designed to confirm safety and efficacy of the BIOTRONIK Sentus OTW QP&#xD;
      left ventricular leads to satisfy FDA requirements for regulatory approval of the leads in&#xD;
      the US. The Sentus OTW QP leads received FDA approval on May 4, 2017.&#xD;
&#xD;
      Long-term safety of the BIOTRONIK Sentus OTW QP left ventricular leads will be confirmed&#xD;
      during the ongoing post approval phase (US sites only).&#xD;
&#xD;
      A protocol update was implemented on September 6, 2019 to transition the long-term follow up&#xD;
      for the ongoing Sentus QP Study to a new EP PASSION real-world data methodology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    BIOTRONIK received FDA approval to transition the ongoing Sentus QP Study to a new EP PASSION&#xD;
    real-world data methodology.&#xD;
  </why_stopped>
  <start_date type="Actual">December 16, 2014</start_date>
  <completion_date type="Actual">January 23, 2020</completion_date>
  <primary_completion_date type="Actual">January 23, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sentus QP Related Complication-free Rate Through 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>The purpose of primary endpoint 1 is to evaluate the Sentus QP related complication-free rate through 6 months post-implant. This is evaluated as a percentage of participants without a complication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Acceptable Pacing Threshold of Sentus QP Lead in Permanently Programmed Vector at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>The purpose of primary endpoint 2 is to evaluate the LV lead pacing threshold for the permanently programmed pacing vector at 3 months post-implant.This was evaluated by performing an exact, binomial test comparing the percentage of participants with acceptable pacing thresholds to a performance goal of 88%. LV threshold values of less than or equal to 2.5 V at 0.4 ms in the permanently programmed vector are considered acceptable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sentus QP Related Complication-free Rate</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The purpose of primary endpoint 3 is to evaluate the Sentus QP related complication-free rate through study termination (post approval phase). This is evaluated as a percentage of participants without a complication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sentus QP Acceptable Pacing Threshold in Permanently Programmed Vector at 3 Months Per Lead Model</measure>
    <time_frame>3 months</time_frame>
    <description>The purpose of the secondary endpoint is to evaluate the LV lead pacing threshold for the permanently programmed pacing vector at 3 months post-implantation in the two different lead types, Sentus OTW QP L and Sentus OTW QP S. This was evaluated as the number of participants with an acceptable pacing threshold out of the total number of patients for each lead model. LV threshold values of less than or equal to 2.5 V at 0.4 ms in the permanently programmed vector is considered acceptable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sentus QP Acceptable Pacing Threshold in Novel Vectors at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>The purpose of this secondary endpoint is to evaluate the number of participants with at least one acceptable LV lead pacing threshold in a novel pacing vector at 3 months post-implantation. This was evaluated as the number of participants with at least one acceptable LV pacing threshold in a novel pacing vector out of the total number of participants with completed novel pacing threshold testing. LV threshold values of less than or equal to 2.5 V at 0.4 ms in a novel pacing vector is considered acceptable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sentus QP Acceptable R-wave Sensed Amplitude at 3 Months Per Lead Model</measure>
    <time_frame>3 months</time_frame>
    <description>The purpose of this secondary endpoint is to evaluate acceptable LV lead sensing amplitude at 3 months post-implantation. This was evaluated as the number of participants with an acceptable LV sensing amplitude out of the total number of participants. R-wave sensed mean amplitude of greater than or equal to 2 mV is considered acceptable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sentus QP Acceptable Pacing Impedance at 3 Months Per Lead Model</measure>
    <time_frame>3 months</time_frame>
    <description>The purpose of this secondary endpoint is to evaluate the acceptable LV lead pacing impedance at 3 months post-implantation. This was evaluated as the number of participants with an acceptable LV pacing impedance out of the total participants. LV impedance values of greater than 200 Ohms and less than 2000 Ohms is considered acceptable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sentus QP Time to Complication</measure>
    <time_frame>6 months</time_frame>
    <description>The purpose of this secondary is to evaluate the Sentus related complication-free rate through 6 months post-implant by the Kaplan-Meier method. The below table shows Kaplan-Meier estimates of the estimated freedom from Sentus related complications at 180 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sentus QP Related Complication-free Rate Per Lead Model</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The purpose of secondary endpoint 7 is to evaluate the Sentus QP related complication-free rate through study termination (post approval phase). This is evaluated as percentage of participants without a complication per lead model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Sentus QP Adverse Event Rates</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The purpose of secondary endpoint 8 is to evaluate the rate of individual types of adverse events related to the Sentus QP lead through study termination (post approval phase). This is evaluated as the percentage of participants with a specific adverse event out of the total participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Successfully Reprogrammed to Resolve Phrenic Nerve Stimulation or High Pacing Threshold</measure>
    <time_frame>12 months</time_frame>
    <description>The purpose of this secondary endpoint is to evaluate the number of participants in whom phrenic nerve stimulation or high LV pacing threshold was be successfully resolved by reprogramming of the LV pacing vector. This is evaluated as the number of participants with successful reprogramming out of all participants experiencing phrenic nerve stimulation or high LV pacing threshold. LV pacing threshold resulting in invasive intervention, or, in the absence of intervention, a lead threshold that has increased two fold from the chronic threshold value, and is unable to achieve a 2:1 safety margin at follow-up is considered a high LV pacing threshold.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2226</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Sentus QP left ventricular lead</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects consented and implanted with a Sentus QP left ventricular lead.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sentus QP left ventricular lead</intervention_name>
    <description>Implantation of quadripolar left ventricular lead in patients with CRT-D indication</description>
    <arm_group_label>Sentus QP left ventricular lead</arm_group_label>
    <other_name>Sentus OTW QP L</other_name>
    <other_name>Sentus OTW QP S</other_name>
    <other_name>Sentus OTW QP S-xx/49</other_name>
    <other_name>Sentus OTW QP L-xx/49</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Standard CRT-D indication according to clinical routine&#xD;
&#xD;
          -  De novo implantation or upgrade from existing ICD or pacemaker implant utilizing a&#xD;
             BIOTRONIK CRT-D system with IS4 LV port and Sentus QP LV lead&#xD;
&#xD;
          -  Patient is able to understand the nature of the clinical investigation and provide&#xD;
             written informed consent&#xD;
&#xD;
          -  Patient is able and willing to complete all routine study visits at the&#xD;
             investigational site through 5 years of follow-up&#xD;
&#xD;
          -  Patient accepts Home Monitoring® concept&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic atrial fibrillation&#xD;
&#xD;
          -  Contraindication to CRT-D therapy&#xD;
&#xD;
          -  Currently implanted with an endocardial or epicardial left ventricular lead or had&#xD;
             prior attempt to place a left ventricular lead&#xD;
&#xD;
          -  Cardiac surgical procedure, such as coronary artery bypass graft or valve surgery that&#xD;
             is planned to occur within 6 months after implant or ablation that is planned to occur&#xD;
             within 90 days after implant (ablations planned to occur prior to or at implant are&#xD;
             not exclusionary)&#xD;
&#xD;
          -  Expected to receive a heart transplant or ventricular assist device within 6 months&#xD;
&#xD;
          -  Life expectancy less than 12 months&#xD;
&#xD;
          -  Participation in any other investigational cardiac clinical investigation during the&#xD;
             course of the study&#xD;
&#xD;
          -  Presence of another life-threatening, underlying illness separate from their cardiac&#xD;
             disorder&#xD;
&#xD;
          -  Pregnant or breast-feeding at time of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Curnis, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Spedali Civili - Universita di Brescia, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mattias Roser, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Charité CBF Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cheyenne</city>
        <state>Wyoming</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Center</name>
      <address>
        <city>Bedford Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyell McEwing Hospital</name>
      <address>
        <city>Elizabeth Vale</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Northern Hospital</name>
      <address>
        <city>Epping</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nambour General Hospital</name>
      <address>
        <city>Nambour</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitets Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DHZ Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Heimsuchung Caritas Klinik Pankow</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immanuel Klinikum Herzzentrum Bernau</name>
      <address>
        <city>Bernau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Krankenhaus Bielefeld Mitte</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta-Kranken-Anstalt Bochum</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta Krankenhaus Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinrich Heine University Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth Krankenhaus Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHZ Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera gGmbH</name>
      <address>
        <city>Gera</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westpfalzklinikum</name>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum St. Georg</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKSH Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Lünen</name>
      <address>
        <city>Lünen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elbekliniken Stade - Buxtehude</name>
      <address>
        <city>Stade</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBK Villingen Schwenningen</name>
      <address>
        <city>Villingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHG-Kliniken Völklingen</name>
      <address>
        <city>Völklingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HBK Zwickau</name>
      <address>
        <city>Zwickau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Sant'Anna Como</name>
      <address>
        <city>Como</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nusch</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vusch East Slovak Cardiology Institute</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonspital Luzern</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Poland</country>
    <country>Portugal</country>
  </removed_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2014</study_first_posted>
  <results_first_submitted>January 25, 2021</results_first_submitted>
  <results_first_submitted_qc>March 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 24, 2021</results_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRT-D therapy</keyword>
  <keyword>quadripolar left ventricular lead</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02290028/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sentus QP Left Ventricular Lead</title>
          <description>Participants consented and implanted with a Sentus QP left ventricular lead and CRT-D, plus participants that were consented but did not receive a Sentus QP lead or CRT-D.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2226"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sentus lead or required CRT-D was not implanted</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer under care of study physician</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sentus lead or required CRT-D explanted</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study site closure</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transition to EP PASSION</title>
              <participants_list>
                <participants group_id="P1" count="1295"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Planned study completion at 12 months</title>
              <participants_list>
                <participants group_id="P1" count="257"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants consented with baseline data collection completed</population>
      <group_list>
        <group group_id="B1">
          <title>Sentus QP Left Ventricular Lead</title>
          <description>Participants consented and implanted with a Sentus QP left ventricular lead and CRT-D.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2222"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Data collected and analyzed when available, not all subjects had data available for this measurement</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2221"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.8" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="683"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Data collected and analyzed when available, not all subjects had data available for this measurement</population>
          <units>Inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Data collected and analyzed when available, not all subjects had data available for this measurement</population>
          <units>Pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197.3" spread="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sentus QP Related Complication-free Rate Through 6 Months</title>
        <description>The purpose of primary endpoint 1 is to evaluate the Sentus QP related complication-free rate through 6 months post-implant. This is evaluated as a percentage of participants without a complication.</description>
        <time_frame>6 months</time_frame>
        <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016.</population>
        <group_list>
          <group group_id="O1">
            <title>Sentus QP Left Ventricular Lead</title>
            <description>Participants consented and implanted with a Sentus QP left ventricular lead and CRT-D.</description>
          </group>
        </group_list>
        <measure>
          <title>Sentus QP Related Complication-free Rate Through 6 Months</title>
          <description>The purpose of primary endpoint 1 is to evaluate the Sentus QP related complication-free rate through 6 months post-implant. This is evaluated as a percentage of participants without a complication.</description>
          <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="94.4" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary endpoint 1 was evaluated by performing an exact, binomial test comparing the observed proportion (overall complication-free rate at 6 months) to the performance goal of 90.0%, with Type I error (alpha) of 0.025 and power of 80%. The lower, two-sided 95% confidence bound for the overall complication-free rate must be greater than 90.0%.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Exact, binomial</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Acceptable Pacing Threshold of Sentus QP Lead in Permanently Programmed Vector at 3 Months</title>
        <description>The purpose of primary endpoint 2 is to evaluate the LV lead pacing threshold for the permanently programmed pacing vector at 3 months post-implant.This was evaluated by performing an exact, binomial test comparing the percentage of participants with acceptable pacing thresholds to a performance goal of 88%. LV threshold values of less than or equal to 2.5 V at 0.4 ms in the permanently programmed vector are considered acceptable.</description>
        <time_frame>3 months</time_frame>
        <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016, and with completed threshold testing at 3 months post-implant or with available data from remote monitoring or next visits (as pre-specified in the protocol).</population>
        <group_list>
          <group group_id="O1">
            <title>Sentus QP Left Ventricular Lead</title>
            <description>Participants consented and implanted with a Sentus QP left ventricular lead and CRT-D.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Acceptable Pacing Threshold of Sentus QP Lead in Permanently Programmed Vector at 3 Months</title>
          <description>The purpose of primary endpoint 2 is to evaluate the LV lead pacing threshold for the permanently programmed pacing vector at 3 months post-implant.This was evaluated by performing an exact, binomial test comparing the percentage of participants with acceptable pacing thresholds to a performance goal of 88%. LV threshold values of less than or equal to 2.5 V at 0.4 ms in the permanently programmed vector are considered acceptable.</description>
          <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016, and with completed threshold testing at 3 months post-implant or with available data from remote monitoring or next visits (as pre-specified in the protocol).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" lower_limit="89.8" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary endpoint 2 was evaluated by performing an exact, binomial test comparing an observed proportion (rate of acceptable LV pacing thresholds at the permanently programmed pacing vector at 3 months) to 88%, with Type I error (alpha) of 0.025 and power of 80%. The lower, two-sided 95% confidence bound for the percentage of subjects with an acceptable LV pacing threshold in the permanently programmed pacing vector must be greater than 88.0%.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.002</p_value>
            <method>Exact, binomial</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sentus QP Related Complication-free Rate</title>
        <description>The purpose of primary endpoint 3 is to evaluate the Sentus QP related complication-free rate through study termination (post approval phase). This is evaluated as a percentage of participants without a complication.</description>
        <time_frame>Up to 4 years</time_frame>
        <population>All participants in the Post-Market cohort, which included all participants who were enrolled with planned 5 year follow-up and were successfully implanted with a Sentus QP left ventricular lead.</population>
        <group_list>
          <group group_id="O1">
            <title>Sentus QP Left Ventricular Lead</title>
            <description>Participants consented and implanted with a Sentus QP left ventricular lead and CRT-D.</description>
          </group>
        </group_list>
        <measure>
          <title>Sentus QP Related Complication-free Rate</title>
          <description>The purpose of primary endpoint 3 is to evaluate the Sentus QP related complication-free rate through study termination (post approval phase). This is evaluated as a percentage of participants without a complication.</description>
          <population>All participants in the Post-Market cohort, which included all participants who were enrolled with planned 5 year follow-up and were successfully implanted with a Sentus QP left ventricular lead.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1727"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.03" lower_limit="97.38" upper_limit="98.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary endpoint 3 will be evaluated by performing an exact, binomial test comparing the observed proportion (overall complication-free rate at 5 years) to the performance goal of 92.5%, with Type I error (alpha) of 0.025 and power of 80%. The lower, two-sided 95% confidence bound for the overall complication-free rate must be greater than 92.5%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <other_analysis_desc>On September 24, 2019, BIOTRONIK received FDA approval to transition the ongoing Sentus Post Approval Registry to a new EP PASSION real-world data methodology. As of study closure, the number of subjects with complete data required to perform the hypothesis test was not met. Therefore, this outcome measure was not analyzed.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sentus QP Acceptable Pacing Threshold in Permanently Programmed Vector at 3 Months Per Lead Model</title>
        <description>The purpose of the secondary endpoint is to evaluate the LV lead pacing threshold for the permanently programmed pacing vector at 3 months post-implantation in the two different lead types, Sentus OTW QP L and Sentus OTW QP S. This was evaluated as the number of participants with an acceptable pacing threshold out of the total number of patients for each lead model. LV threshold values of less than or equal to 2.5 V at 0.4 ms in the permanently programmed vector is considered acceptable.</description>
        <time_frame>3 months</time_frame>
        <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016, and with completed threshold testing at 3 months post-implant.</population>
        <group_list>
          <group group_id="O1">
            <title>Sentus QP L Model Left Ventricular Lead</title>
            <description>Participants consented and implanted with a Sentus QP L model left ventricular lead and CRT-D.</description>
          </group>
          <group group_id="O2">
            <title>Sentus QP S Model Left Ventricular Lead</title>
            <description>Participants consented and implanted with a Sentus QP S model left ventricular lead and CRT-D.</description>
          </group>
        </group_list>
        <measure>
          <title>Sentus QP Acceptable Pacing Threshold in Permanently Programmed Vector at 3 Months Per Lead Model</title>
          <description>The purpose of the secondary endpoint is to evaluate the LV lead pacing threshold for the permanently programmed pacing vector at 3 months post-implantation in the two different lead types, Sentus OTW QP L and Sentus OTW QP S. This was evaluated as the number of participants with an acceptable pacing threshold out of the total number of patients for each lead model. LV threshold values of less than or equal to 2.5 V at 0.4 ms in the permanently programmed vector is considered acceptable.</description>
          <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016, and with completed threshold testing at 3 months post-implant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sentus QP Acceptable Pacing Threshold in Novel Vectors at 3 Months</title>
        <description>The purpose of this secondary endpoint is to evaluate the number of participants with at least one acceptable LV lead pacing threshold in a novel pacing vector at 3 months post-implantation. This was evaluated as the number of participants with at least one acceptable LV pacing threshold in a novel pacing vector out of the total number of participants with completed novel pacing threshold testing. LV threshold values of less than or equal to 2.5 V at 0.4 ms in a novel pacing vector is considered acceptable.</description>
        <time_frame>3 months</time_frame>
        <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016, and with completed novel vector threshold testing at 3 months post-implant.</population>
        <group_list>
          <group group_id="O1">
            <title>Sentus QP Left Ventricular Lead</title>
            <description>Participants consented and implanted with a Sentus QP left ventricular lead and CRT-D.</description>
          </group>
        </group_list>
        <measure>
          <title>Sentus QP Acceptable Pacing Threshold in Novel Vectors at 3 Months</title>
          <description>The purpose of this secondary endpoint is to evaluate the number of participants with at least one acceptable LV lead pacing threshold in a novel pacing vector at 3 months post-implantation. This was evaluated as the number of participants with at least one acceptable LV pacing threshold in a novel pacing vector out of the total number of participants with completed novel pacing threshold testing. LV threshold values of less than or equal to 2.5 V at 0.4 ms in a novel pacing vector is considered acceptable.</description>
          <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016, and with completed novel vector threshold testing at 3 months post-implant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sentus QP Acceptable R-wave Sensed Amplitude at 3 Months Per Lead Model</title>
        <description>The purpose of this secondary endpoint is to evaluate acceptable LV lead sensing amplitude at 3 months post-implantation. This was evaluated as the number of participants with an acceptable LV sensing amplitude out of the total number of participants. R-wave sensed mean amplitude of greater than or equal to 2 mV is considered acceptable.</description>
        <time_frame>3 months</time_frame>
        <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016, and with completed sensing test at 3 months post-implant.</population>
        <group_list>
          <group group_id="O1">
            <title>Sentus QP L Model Left Ventricular Lead</title>
            <description>Participants consented and implanted with a Sentus QP L model left ventricular lead and CRT-D.</description>
          </group>
          <group group_id="O2">
            <title>Sentus QP S Model Left Ventricular Lead</title>
            <description>Participants consented and implanted with a Sentus QP S model left ventricular lead and CRT-D.</description>
          </group>
        </group_list>
        <measure>
          <title>Sentus QP Acceptable R-wave Sensed Amplitude at 3 Months Per Lead Model</title>
          <description>The purpose of this secondary endpoint is to evaluate acceptable LV lead sensing amplitude at 3 months post-implantation. This was evaluated as the number of participants with an acceptable LV sensing amplitude out of the total number of participants. R-wave sensed mean amplitude of greater than or equal to 2 mV is considered acceptable.</description>
          <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016, and with completed sensing test at 3 months post-implant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sentus QP Acceptable Pacing Impedance at 3 Months Per Lead Model</title>
        <description>The purpose of this secondary endpoint is to evaluate the acceptable LV lead pacing impedance at 3 months post-implantation. This was evaluated as the number of participants with an acceptable LV pacing impedance out of the total participants. LV impedance values of greater than 200 Ohms and less than 2000 Ohms is considered acceptable.</description>
        <time_frame>3 months</time_frame>
        <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016, and with completed impedance testing at 3 months post-implant.</population>
        <group_list>
          <group group_id="O1">
            <title>Sentus QP L Model Left Ventricular Lead</title>
            <description>Participants consented and implanted with a Sentus QP L model left ventricular lead and CRT-D.</description>
          </group>
          <group group_id="O2">
            <title>Sentus QP S Model Left Ventricular Lead</title>
            <description>Participants consented and implanted with a Sentus QP S model left ventricular lead and CRT-D.</description>
          </group>
        </group_list>
        <measure>
          <title>Sentus QP Acceptable Pacing Impedance at 3 Months Per Lead Model</title>
          <description>The purpose of this secondary endpoint is to evaluate the acceptable LV lead pacing impedance at 3 months post-implantation. This was evaluated as the number of participants with an acceptable LV pacing impedance out of the total participants. LV impedance values of greater than 200 Ohms and less than 2000 Ohms is considered acceptable.</description>
          <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016, and with completed impedance testing at 3 months post-implant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sentus QP Time to Complication</title>
        <description>The purpose of this secondary is to evaluate the Sentus related complication-free rate through 6 months post-implant by the Kaplan-Meier method. The below table shows Kaplan-Meier estimates of the estimated freedom from Sentus related complications at 180 days.</description>
        <time_frame>6 months</time_frame>
        <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016.</population>
        <group_list>
          <group group_id="O1">
            <title>Sentus QP Left Ventricular Lead</title>
            <description>Participants consented and implanted with a Sentus QP left ventricular lead and CRT-D.</description>
          </group>
        </group_list>
        <measure>
          <title>Sentus QP Time to Complication</title>
          <description>The purpose of this secondary is to evaluate the Sentus related complication-free rate through 6 months post-implant by the Kaplan-Meier method. The below table shows Kaplan-Meier estimates of the estimated freedom from Sentus related complications at 180 days.</description>
          <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="95.14" upper_limit="99.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sentus QP Related Complication-free Rate Per Lead Model</title>
        <description>The purpose of secondary endpoint 7 is to evaluate the Sentus QP related complication-free rate through study termination (post approval phase). This is evaluated as percentage of participants without a complication per lead model.</description>
        <time_frame>Up to 4 years</time_frame>
        <population>All participants in the Post-Market cohort, which included all participants who were enrolled with planned 5 year follow-up and were successfully implanted with a Sentus QP left ventricular lead.</population>
        <group_list>
          <group group_id="O1">
            <title>Sentus QP L Model Left Ventricular Lead</title>
            <description>Participants consented and implanted with a Sentus QP L model left ventricular lead and CRT-D.</description>
          </group>
          <group group_id="O2">
            <title>Sentus QP S Model Left Ventricular Lead</title>
            <description>Participants consented and implanted with a Sentus QP S model left ventricular lead CRT-D.</description>
          </group>
        </group_list>
        <measure>
          <title>Sentus QP Related Complication-free Rate Per Lead Model</title>
          <description>The purpose of secondary endpoint 7 is to evaluate the Sentus QP related complication-free rate through study termination (post approval phase). This is evaluated as percentage of participants without a complication per lead model.</description>
          <population>All participants in the Post-Market cohort, which included all participants who were enrolled with planned 5 year follow-up and were successfully implanted with a Sentus QP left ventricular lead.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1306"/>
                <count group_id="O2" value="421"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.47" lower_limit="97.80" upper_limit="99.13"/>
                    <measurement group_id="O2" value="96.67" lower_limit="94.96" upper_limit="98.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Sentus QP Adverse Event Rates</title>
        <description>The purpose of secondary endpoint 8 is to evaluate the rate of individual types of adverse events related to the Sentus QP lead through study termination (post approval phase). This is evaluated as the percentage of participants with a specific adverse event out of the total participants.</description>
        <time_frame>Up to 4 years</time_frame>
        <population>All participants in the Post-Market cohort, which included all participants who were enrolled with planned 5 year follow-up and were successfully implanted with a Sentus QP left ventricular lead.</population>
        <group_list>
          <group group_id="O1">
            <title>Sentus QP Left Ventricular Lead</title>
            <description>Participants consented and implanted with a Sentus QP left ventricular lead and CRT-D.</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Sentus QP Adverse Event Rates</title>
          <description>The purpose of secondary endpoint 8 is to evaluate the rate of individual types of adverse events related to the Sentus QP lead through study termination (post approval phase). This is evaluated as the percentage of participants with a specific adverse event out of the total participants.</description>
          <population>All participants in the Post-Market cohort, which included all participants who were enrolled with planned 5 year follow-up and were successfully implanted with a Sentus QP left ventricular lead.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1727"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dislodgements</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" lower_limit="0.08" upper_limit="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extracardiac Stimulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.04" upper_limit="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mechanical Lead Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0.01" upper_limit="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated Lead Impedance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0.01" upper_limit="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated LV Pacing Threshold</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.00" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Electrical Lead Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.00" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac Perforation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.00" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Successfully Reprogrammed to Resolve Phrenic Nerve Stimulation or High Pacing Threshold</title>
        <description>The purpose of this secondary endpoint is to evaluate the number of participants in whom phrenic nerve stimulation or high LV pacing threshold was be successfully resolved by reprogramming of the LV pacing vector. This is evaluated as the number of participants with successful reprogramming out of all participants experiencing phrenic nerve stimulation or high LV pacing threshold. LV pacing threshold resulting in invasive intervention, or, in the absence of intervention, a lead threshold that has increased two fold from the chronic threshold value, and is unable to achieve a 2:1 safety margin at follow-up is considered a high LV pacing threshold.</description>
        <time_frame>12 months</time_frame>
        <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016, and whom experienced phrenic nerve stimulation or high LV pacing threshold.</population>
        <group_list>
          <group group_id="O1">
            <title>Sentus QP Left Ventricular Lead</title>
            <description>Participants consented and implanted with a Sentus QP left ventricular lead and CRT-D.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Successfully Reprogrammed to Resolve Phrenic Nerve Stimulation or High Pacing Threshold</title>
          <description>The purpose of this secondary endpoint is to evaluate the number of participants in whom phrenic nerve stimulation or high LV pacing threshold was be successfully resolved by reprogramming of the LV pacing vector. This is evaluated as the number of participants with successful reprogramming out of all participants experiencing phrenic nerve stimulation or high LV pacing threshold. LV pacing threshold resulting in invasive intervention, or, in the absence of intervention, a lead threshold that has increased two fold from the chronic threshold value, and is unable to achieve a 2:1 safety margin at follow-up is considered a high LV pacing threshold.</description>
          <population>All participants in the Pre-Market cohort, defined as the study participants who were consented and implanted with a Sentus QP LV lead on or before January 29, 2016, and whom experienced phrenic nerve stimulation or high LV pacing threshold.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Though study exit or study termination, an average of 1.2 years, and up to 4 years</time_frame>
      <desc>According to the study protocol, sites were required to report all deaths and all adverse events that were considered related to the implant procedure, implanted pulse generator, or implanted leads. Adverse events determined to be not related to the implant procedure, implanted pulse generator, or implanted leads were not collected.&#xD;
Reported adverse events were defined as a serious or 'other' adverse event according to the clinicaltrials.gov definition.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sentus QP Left Ventricular Lead</title>
          <description>Participants consented and implanted with a Sentus QP left ventricular lead and CRT-D.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="290" subjects_at_risk="2226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac perforation associated with the RA lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Cardiac perforation associated with the RV lead</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Cardiac perforation associated with the LV lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Inability to place LV lead</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RA lead related lead dislodgement</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RV lead related lead dislodgement</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RV lead related elevated pacing threshold</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RV lead impedance out of range, high impedance</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RV lead related clinical failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RV lead related mechanical failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RV lead undersensing or loss of sensing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Endocarditis associated with the RV lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related lead dislodgement</sub_title>
                <counts group_id="E1" events="66" subjects_affected="59" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related extracardiac stimulation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related mechanical failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related high pacing threshold</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related elevated pacing threshold</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related clinical failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related loss of capture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>ICD device migration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>ICD device related inappropriate shock or ATP</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>ICD device related electronic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RA lead elevated pacing threshold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead electrical lead failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead impedance out of range, high</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Twiddler's syndrome</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Implant procedure related infection</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Secondary infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Pocket infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac perforation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Arrhythmia associated with implant procedure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Loose set-screw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Wound healing disturbance</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Discomfort/pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Post surgical bleeding</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Post procedure anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Allergy to contrast agent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Elevated WBD and labs post procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Inflammation and swelling at surgical site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="711" subjects_at_risk="2226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Inability to place LV lead</sub_title>
                <counts group_id="E1" events="101" subjects_affected="101" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RA lead related lead dislodgement</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RA lead related undersensing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RV lead related clinical failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RV lead related extracardiac stimulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RV lead related high pacing threshold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RV lead related oversensing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related extracardiac stimulation</sub_title>
                <counts group_id="E1" events="316" subjects_affected="258" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related elevated pacing threshold</sub_title>
                <counts group_id="E1" events="147" subjects_affected="132" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related lead dislodgement</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related loss of capture</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead impedance out of range, high impedance</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related high pacing threshold</sub_title>
                <counts group_id="E1" events="40" subjects_affected="38" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related clinical failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related oversensing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related mechanical failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related electrical failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>LV lead related loss of sensing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>ICD device migration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>ICD device related inappropriate shock or ATP</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>ICD device related housing defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>ICD device related high defibrillator (DFT) testing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>ICD device related pacemaker mediated tachycardia (PMT)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RA lead elevated pacing threshold</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RA lead related extracardiac stimulation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>RA lead related thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Twiddler's syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Rachet syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Implant procedure related infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia associated with implant procedure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Coronary sinus dissection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Loose set-screw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Bleeding at surgical site</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Allergy to surgery prep</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Unsuccessful defibrillator threshold (DFT) testing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Wound healing disturbance</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Discomfort/pain at surgical site</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Pain in shoulder after system revision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Hypotension after insertion procedure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Bleeding caused by surgical prep</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Fever after insertion procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
              <event>
                <sub_title>Emesis after insertion procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2226"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Manager, Scientific Affairs</name_or_title>
      <organization>BIOTRONIK, Inc.</organization>
      <phone>1-800-547-0394</phone>
      <email>crystal.miller@biotronik.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

